Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00428701 · ClinicalTrials.gov registry record · Phase 4

An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium

A Phase 4 study of Gastric Ulcer, sponsored by AstraZeneca.

Completed
Registry status
Phase 4
Development phase
40
Enrollment target
5
Study locations

NCT00428701: Completed Phase 4 study of Gastric Ulcer, sponsored by AstraZeneca.

NCT00428701 is a Phase 4 study of Gastric Ulcer that has completed, run by AstraZeneca. The registered enrollment target is 40 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00428701, a Phase 4 study of Gastric Ulcer, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 4
Development phase
40 participants
Enrollment target
5
Study locations

Study Summary

This study is being done to see if Nexium I.V. can reduce and control stomach acid in mechanically ventilated, critically ill patients in an Intensive Care Unit setting.

Conditions Studied

Interventions

  • DRUG Esomeprazole Sodium

Study Locations (5)

Tennessee

  • Research Site - Memphis
  • Research Site - Nashville

Delaware

  • Research SIte - Newark

Louisiana

  • Research Site - Shreveport

Pennsylvania

  • Research Site - Hershey

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2006-10
Est. Completion 2006-11
Phase Phase 4
AstraZeneca

1,285 total trials

What the finished NCT00428701 record still lists

NCT00428701 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Gastric Ulcer appearing as the primary indexed condition, and to 1 intervention - of which Esomeprazole Sodium is the first listed.

NCT00428701 lists 5 locations in 4 states (Tennessee, Delaware, Louisiana).

Frequently Asked Questions

What is clinical trial NCT00428701 about?

NCT00428701 is a clinical study titled "An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium". This study is being done to see if Nexium I.V. can reduce and control stomach acid in mechanically ventilated, critically ill patients in an Intensive Care Unit setting.

What is the current status of trial NCT00428701?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2006-10. Estimated completion is 2006-11.

What conditions does trial NCT00428701 study?

This clinical trial studies the following conditions: Gastric Ulcer.

What interventions are being tested in trial NCT00428701?

The interventions under investigation include: Esomeprazole Sodium (DRUG).

Who is sponsoring clinical trial NCT00428701?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00428701 being conducted?

This trial has 5 study locations across Delaware, Louisiana, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gastric Ulcer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00428701's enrollment target sits among peer trials

40 1397th of 2000 higher than 534 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00428701, the US trial registry maintained by the National Library of Medicine. NCT00428701 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.